Welcome to our dedicated page for IO Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IO Biotech SEC filings document the company's transition from a Nasdaq-listed clinical-stage biopharmaceutical issuer to a Chapter 7 bankruptcy case after ceasing operations. The filings record trustee control over assets and liabilities, liquidation proceedings, related debt-default matters, and the limited recovery expectations disclosed for common stockholders.
Earlier filings cover quarterly operating updates, investor presentation materials, Nasdaq continued-listing compliance, workforce-reduction and exit-cost disclosures, officer and principal accounting officer changes, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory updates tied to the company's T-win cancer vaccine programs.
IO Biotech, Inc. filed a current report stating that on January 21, 2026 it issued a press release announcing that it plans to explore strategic alternatives. This means the company is formally beginning a review of potential options for its future direction, which can range from continuing its current plan to considering significant corporate changes, depending on what the review determines. The press release describing this process is attached as an exhibit to the report.
IO Biotech, Inc. reported that its Senior Vice President and Chief Accounting Officer, Brian Burkavage, has informed the company of his intent to resign effective December 12, 2025 to pursue another opportunity. The company stated that his resignation is not due to any dispute or disagreement with the company.
The company’s Chief Financial Officer, Amy Sullivan, has been designated as IO Biotech’s principal accounting officer, effective upon Mr. Burkavage’s departure. Her background is described in the company’s 2025 definitive proxy statement. IO Biotech noted that no new compensatory arrangements will be entered into with Ms. Sullivan in connection with her additional role.
IO Biotech, Inc. announced that it will participate in the Jefferies Global Healthcare Conference beginning on November 18, 2025. In connection with this event, the company prepared an updated corporate investor presentation that it plans to use at the conference and in meetings with investors.
The updated investor presentation, referred to as the Investor Deck, was posted to the company’s website on November 18, 2025 and is also provided as an exhibit to this report. The company notes that this material is being furnished rather than filed under U.S. securities laws.
IO Biotech (IOBT) reported Q3 results showing lower operating expenses but continued losses and tighter liquidity. Operating costs were $19.4M in Q3 (vs. $26.5M a year ago), driving a net loss of $8.4M. For the first nine months, operating expenses were $65.1M and net loss was $57.0M. Cash, cash equivalents and restricted cash were $30.9M at September 30, 2025.
The company disclosed substantial doubt about its ability to continue as a going concern, stating current cash is not sufficient to fund operations for at least 12 months from issuance. To extend runway, IO Biotech drew on the European Investment Bank facility, funding €10.0M (Tranche A) and €12.5M (Tranche B), resulting in $16.7M term loan debt, net, and issuing related liability-classified warrants valued at $3.4M at quarter-end.
Management also launched a restructuring on September 26, 2025 to reduce workforce by roughly 50%, expecting $1.0–$1.5M in charges, with $0.9M recognized in Q3. The company raised $6.6M net through its ATM (3,810,040 shares issued). Shares outstanding were 69,692,179 as of September 30, 2025; 71,948,842 were outstanding as of November 10, 2025.
IO Biotech, Inc. (IOBT) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and an operations update. The press release is attached as Exhibit 99.1.
The company states the information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
IO Biotech, Inc. reported that its board approved a major restructuring and workforce reduction plan to conserve capital and focus on developing Cylembio. The plan will cut approximately 50% of the company’s global workforce.
The company expects to record one-time charges of about $1.0 million to $1.5 million, mainly for severance, continued healthcare, earned vacation and related termination costs, largely in the third quarter of 2025, with payments expected to be completed by the fourth quarter of 2025.
IO Biotech also disclosed that the FDA has recommended it not submit a BLA based on data from the IOB-013 clinical trial, which showed improved progression-free survival for Cylembio plus pembrolizumab but narrowly missed statistical significance. The company plans further discussions with the FDA and European regulators on an additional potential registrational study and possible paths to approval in the United States and European Union.
Amendment No. 7 to Schedule 13D reports that on August 11, 2025 Novo Holdings A/S sold 841,996 shares of IO Biotech common stock at $1.7673 per share in a block trade. After the transaction Novo Holdings beneficially owns 2,512,453 shares and 2,469,135 shares issuable upon exercise of immediately exercisable warrants, which together represent approximately 7.3% of IO Biotech's common stock on a fully counted basis using 65,880,914 outstanding shares. The filing updates the reporting schedule originally submitted in 2021 and confirms Novo Holdings' sole voting and dispositive power over its shares.
IO Biotech reported mixed clinical and financing developments in its Form 10-Q. In a global Phase 3 trial of Cylembio (IO102-IO103) plus pembrolizumab versus pembrolizumab alone in first-line advanced melanoma (407 patients), the combination achieved a median progression-free survival of 19.4 months versus 11.0 months for pembrolizumab alone, with a hazard ratio of 0.77 [95% CI: 0.58-1.00; p=0.056], narrowly missing the pre-specified threshold for statistical significance. An early trend toward improved overall survival was observed (HR 0.79) with results expected to mature in the next six to nine months.
On funding, the company completed a private placement that generated $71.9 million net proceeds and has drawn Tranche A (2.5 million? note: Tranche A funded .0 million) and Tranche B (.5 million) under an EIB loan facility; Tranche C of up to .0 million (.0 million.0? see notes) remains subject to conditions including raising an additional $50.0 million and regulatory milestones. The company disclosed substantial doubt about its ability to continue as a going concern and that additional funding will be required. Earlier clinical data cited include a Phase 1/2 trial with confirmed ORR 73%, CRR 50% and median PFS 25.5 months. IO112 IND filing is anticipated in 2026.
IO Biotech, Inc. filed a current report to note that it has released its financial results for the fiscal quarter ended June 30, 2025. The company issued a press release on August 14, 2025 sharing quarterly results and providing an update on its operations for the same period.
The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
IO Biotech disclosed topline results from its Phase 3 IOB-013 study evaluating Cylembio plus pembrolizumab versus pembrolizumab alone as first-line treatment for unresectable or metastatic melanoma. The randomized trial enrolled 407 patients (203 combination, 204 monotherapy). The primary endpoint, progression-free survival assessed by blinded independent review per RECIST v1.1, showed early and sustained separation with a hazard ratio (HR) of 0.77 (95% CI: 0.58–1.00; p=0.056), and median PFS of 19.4 months versus 11.0 months. The primary result falls short of the prespecified significance threshold.
Notable subgroup findings include a pronounced benefit in PD-L1 negative tumors (HR 0.54; mPFS 16.6 vs 3.0 months; nominal p=0.006) and in patients without prior anti–PD-1 therapy (post hoc HR 0.74; mPFS 24.8 vs 11.0 months; nominal p=0.037). Overall survival trends were favorable but immature (HR 0.79; 95% CI: 0.57–1.10). The combination was generally well tolerated; injection site reactions were most common (reported in 56% of combination arm patients) and resolved on treatment. The company plans regulatory discussions about a potential BLA and will present more detailed data. It disclosed an estimated cash balance of approximately $28.1 million plus a €12.5 million tranche drawn under a term loan, which it expects to fund operations into the first quarter of 2026, subject to final close procedures.